TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pharma Mar SA ( (ES:PHM) ) has provided an update.
Pharma Mar SA announced that its Chairman and Chief Financial Officer will present to shareholders at the Ordinary General Meeting in Colmenar Viejo, Madrid. This meeting is significant for stakeholders as it provides insights into the company’s current operations and future strategies.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
More about Pharma Mar SA
Pharma Mar SA is a biopharmaceutical company focusing on the discovery and development of marine-derived drugs for oncology treatment. The company is a leader in the biotechnology industry, with a strong emphasis on innovation and research in cancer therapeutics.
Average Trading Volume: 65,804
Technical Sentiment Signal: Buy
Current Market Cap: €1.47B
For an in-depth examination of PHM stock, go to TipRanks’ Overview page.